---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-25-000082"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:01:12.055724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Bionano Q2 2025 revenue $6.7M (-13% YoY); gross margin 52% vs 33%; flowcell sales +17%

## Summary
- Total revenue $6.7M (-13% YoY); prior year included $0.7M discontinued clinical services; adjusted consumables/software/services up 11%.
- Gross margin 52% (non-GAAP 52%) vs 33% a year ago; operating expenses cut 42% to $11.3M.
- Sold 7,233 flowcells (+17% YoY); installed OGM base 378 systems (+4% YoY).
- Full-year 2025 revenue reaffirmed $26-30M; Q3 2025 guidance $6.7-7.2M; cash runway into Q1 2026.

## SEC filing metadata
- accession: 0001411690-25-000082
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000082/0001411690-25-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000082/bngo-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-25-000082
- JSON: https://secwatch.observer/filing/0001411690-25-000082.json
- Plain text: https://secwatch.observer/filing/0001411690-25-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.